Research Topics | Chris ParkerSummaryAffiliation: Institute of Cancer Research Country: UK Publications
| Collaborators
|
Detail Information
Publications
Prolonging survival in prostate cancer: chemotherapy will have an important roleChris Parker
Academic Unit of Radiotherapy and Oncology, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
BJU Int 96:2-3. 2005- Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): a new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomyChris Parker
Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research and the Royal, Marsden NHS Foundation Trust, Sutton, Surrey, UK
BJU Int 99:1376-9. 2007 - The role of hemoglobin concentration in clinically localized prostate cancer treated with radical radiotherapy +/- neoadjuvant androgen deprivationChris Parker
Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research and the Royal Marsden NHS Trust, Sutton, Surrey, United Kingdom
Int J Radiat Oncol Biol Phys 58:53-8. 2004..01), and (for the NAD + RT data set) T stage (p < 0.001), but not pre-NAD Hb (p = 0.24) or pre-RT Hb (p > 0.3). CONCLUSION: Hemoglobin level is not an important determinant of RT outcome in localized prostate cancer... - Active surveillance: towards a new paradigm in the management of early prostate cancerChris Parker
Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK
Lancet Oncol 5:101-6. 2004..In the longer term, active surveillance may accelerate progress towards a new treatment paradigm for early prostate cancer based on the selective use of therapies designed, not to eradicate the disease, but to alter its natural history... - Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancerJohann Sebastian de Bono
Drug Development Unit and Department of Academic Urology, Royal Marsden Hospital, Centre for Cancer Therapeutics, Institute for Cancer Research, Surrey, United Kingdom
J Clin Oncol 25:257-62. 2007..To determine the prostate-specific antigen (PSA) 50% decline rate within 24 weeks of starting treatment with single-agent pertuzumab in castrate patients with hormone-refractory prostate cancer (HRPC)... - Early outcomes of active surveillance for localized prostate cancerClaire Hardie
Academic Unit of Radiotherapy and Oncology, The Royal Marsden NHS Trust and Institute of Cancer Research, Sutton, Surrey, UK
BJU Int 95:956-60. 2005..Ongoing studies are seeking to optimize the AS protocol, and to compare the long-term outcomes with those of immediate radical treatment... - Prostate-specific antigen velocity in untreated, localized prostate cancerRamachandran Venkitaraman
Academic Unit of Radiotherapy and Oncology, Royal Marsden Hospital and Institute of Cancer Research, Sutton, Surrey, UK
BJU Int 101:161-4. 2008.... - Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort studyRoy Vergis
Institute of Cancer Research, Sutton, UK
Lancet Oncol 9:342-51. 2008..We aimed to study the predictive value of intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer, both in patients treated with radiotherapy and in those treated surgically... - Prostate-specific antigen (PSA) kinetics in untreated, localized prostate cancer: PSA velocity vs PSA doubling timeMichael K Ng
Academic Unit Urology, Royal Marsden Hospital, Sutton, UK
BJU Int 103:872-6. 2009.... - Predictors of histological disease progression in untreated, localized prostate cancerRamachandran Venkitaraman
Academic Unit of Radiotherapy and Oncology, Institute of Cancer Research, Royal Marsden National Health Service Foundation Trust, Sutton, United Kingdom
J Urol 178:833-7. 2007..There is no consensus on the need for or optimum timing of repeat biopsies as part of active surveillance... - Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalationRoy Vergis
Academic Urology Unit, Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Surrey, UK
Int J Radiat Oncol Biol Phys 78:35-41. 2010..We analyzed tumor expression of apoptotic markers with respect to outcome in men with localized prostate cancer in two randomized controlled trials of radiotherapy dose escalation... - Adjuvant vs. salvage radiotherapy for pathologically advanced prostate cancerGerard P McVey
Institute of Cancer Research, Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK
Curr Opin Urol 20:229-33. 2010..It has a particular focus on the debate concerning the optimum timing of postoperative radiotherapy: adjuvant treatment for all high-risk cases vs. salvage treatment at the time of prostate-specific antigen relapse... - A more selective approach to prostate biopsy could be a safe and effective form of prostate cancer 'prevention'Chris Parker
Academic Urology Unit, Institute of Cancer Research and Royal Marsden Hospital, Sutton, Surrey, UK
BJU Int 100:488-90. 2007 - What is low-risk prostate cancer and what is its natural history?Helen O'Donnell
Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK
World J Urol 26:415-22. 2008..Such markers could be used to distinguish those men with truly indolent disease, suitable for observation, from those with significant prostate cancer that stand to benefit from treatment... - Identification of seven new prostate cancer susceptibility loci through a genome-wide association studyRosalind A Eeles
The Institute of Cancer Research, Sutton, Surrey, UK
Nat Genet 41:1116-21. 2009..In addition to replicating previous associations, we identified seven new prostate cancer susceptibility loci on chromosomes 2, 4, 8, 11 and 22 (with P = 1.6 x 10(-8) to P = 2.7 x 10(-33))... - Treating prostate cancer with radiotherapyAnna Wilkins
Academic Urology Unit, Institute of Cancer Research, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK
Nat Rev Clin Oncol 7:583-9. 2010..It is likely that recent technical advances, such as intensity modulation and image guidance, will further improve the toxicity profile of prostate radiotherapy... - The Scandinavian Prostate Cancer Group Study: the case for conservative managementChris Parker
Academic Unit of Radiotherapy and Oncology, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, UK
BJU Int 96:952-3. 2005 - Editorial comment on: Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomyChris Parker
Eur Urol 52:1651-2. 2007 - Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonistsDerek R Wilke
Department of Radiation Oncology, Nova Scotia Cancer Centre, Capital Health, Halifax, Nova Scotia, Canada
BJU Int 97:963-8. 2006..Few men recover potency and sexual desire. The patients age and LH/TT ratio may be predictive of the time to recovery of both supracastrate and normal testosterone levels... - Does active surveillance for men with localized prostate cancer carry psychological morbidity?Katriina L Burnet
Psychological Medicine, Royal Marsden NHS Foundation Trust, London, UK
BJU Int 100:540-3. 2007.... - Systemic vasculitis presenting with acute gastrointestinal hemorrhage: case report and review of the literatureChad M Sisk
Department of Gastroenterology, Brooke Army Medical Center, San Antonio, Texas, USA
Dig Dis Sci 48:1782-5. 2003 - Polarographic electrode study of tumor oxygenation in clinically localized prostate cancerChris Parker
Department of Biostatistics, Princess Margaret Hospital, Toronto, ON, Canada
Int J Radiat Oncol Biol Phys 58:750-7. 2004..HP(5), as determined in this study, should adequately discriminate among patients with prostate cancer and allow the independent prognostic significance of oxygenation to be evaluated once the study matures... - Watchful waiting, temporarily deferred therapy, or active surveillance?Chris Parker
J Clin Oncol 23:1322; author reply 1322-3. 2005 - Adjuvant radiotherapy after surgery for prostate cancerChris Parker
JAMA 300:2119; author reply 2119. 2008 - Role of neoadjuvant androgen deprivation before radical prostate radiotherapyChris Parker
Lancet Oncol 6:819-21. 2005 - Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control studyJulia Hippisley-Cox
Division of Primary Care, University of Nottingham, 13th Floor Tower Bldg, University Park, Nottingham NG7 2RD, England
Arch Gen Psychiatry 64:1368-76. 2007..There is conflicting evidence on whether people with schizophrenia have a different risk of cancer from that of the general population... - Recruiting older people into a large, community-based study of heart failureSarah Barnes
Sheffield Institute for Studies on Ageing, University of Sheffield, Elmfield, Northumberland Road, Sheffield, S10 2TU, UK
Chronic Illn 1:321-9. 2005..The paper concludes that prospective longitudinal studies are of particular relevance to chronic illness, and the complexity of setting up such research must be acknowledged and appropriately resourced... - Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation responseMichael Milosevic
Radiation Medicine Program, Department of Medical Imaging, Princess Margaret Hospital, Toronto, Ontario, Canada
Cancer Res 67:6022-5. 2007.... - Re: All-cause mortality in randomized trials of cancer screeningChris Parker
J Natl Cancer Inst 94:861-2; author reply 865-6. 2002